Annals of hematology · 2020
COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marchetti Monia
Аннотация
COVID-19 pandemia is a major health emergency causing hundreds of deaths worldwide. The high reported morbidity has been related to hypoxia and inflammation leading to endothelial dysfunction and aberrant coagulation in small and large vessels. This review addresses some of the pathways leading to endothelial derangement, such as complement, HIF-1α, and ABL tyrosine kinases. This review also highlights potential targets for prevention and therapy of COVID-19-related organ damage and discusses the role of marketed drugs, such as eculizumab and imatinib, as suitable candidates for clinical trials.
Предметные рубрики MeSH
Antibodies, Monoclonal, HumanizedBetacoronavirusCOVID-19Clinical Trials, Phase II as TopicComplement Inactivating AgentsCoronavirus InfectionsDrug Delivery SystemsEndothelium, VascularHumansHypoxia-Inducible Factor 1, alpha SubunitImatinib MesylatePandemicsPneumonia, ViralProtein-Tyrosine KinasesSARS-CoV-2Signal Transduction